Sangamo Therapeutics filed amended monthly operating reports for July and August, plus a report for September, with its ongoing Chapter 11 case in the U.S. Bankruptcy Court for the District of Delaware. The company sold assets outside the ordinary course of business for $2.3 million in August and $161 million in September, bringing cumulative proceeds to $163.3 million against costs of $32.2 million. Cash on hand rose to $138.5 million at month-end, while total assets reached $264.2 million and prepetition unsecured debt stood at approximately $61.6 million. The company operates in the biotechnology sector, developing gene-editing therapies.
